Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Harpoon Therapeutics Inc (HARP)

Harpoon Therapeutics Inc (HARP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 389,605
  • Shares Outstanding, K 16,932
  • Annual Sales, $ 31,920 K
  • Annual Income, $ -67,730 K
  • 60-Month Beta 2.11
  • Price/Sales 2.28
  • Price/Cash Flow N/A
  • Price/Book 20.82
Trade HARP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -8.76
  • Most Recent Earnings $-0.46 on 11/09/23
  • Next Earnings Date 03/25/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.52
  • Number of Estimates 5
  • High Estimate -0.03
  • Low Estimate -0.74
  • Prior Year -5.50
  • Growth Rate Est. (year over year) +90.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.32 +3.09%
on 02/09/24
23.21 -0.86%
on 03/07/24
+0.67 (+3.00%)
since 02/08/24
3-Month
8.44 +172.63%
on 12/12/23
23.21 -0.86%
on 03/07/24
+14.07 (+157.38%)
since 12/08/23
52-Week
3.11 +639.87%
on 10/12/23
23.21 -0.86%
on 03/07/24
+15.76 (+217.38%)
since 03/08/23

Most Recent Stories

More News
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

Investors are still excited about obesity treatments and weight-management drugs.

MRK : 130.72 (+0.81%)
LLY : 883.88 (-0.24%)
NVO : 141.96 (+0.69%)
HARP : 23.01 (+0.09%)
This 1 Bullish Move by Merck Could Drive Growth for Years to Come

It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.

AMGN : 308.16 (-0.56%)
MRK : 130.72 (+0.81%)
HARP : 23.01 (+0.09%)
Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise, Monday, 1/8/2024

Stocks that traded heavily or had substantial price changes on Monday: Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise

HARP : 23.01 (+0.09%)
ANSS : 325.35 (-0.10%)
MKKGY : 35.8350 (+0.43%)
ALK : 41.18 (-0.39%)
BA : 176.56 (+0.15%)
Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Big Tech Earnings

December S&P 500 futures (ESZ23) are down -0.76%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.92% this morning as the benchmark U.S. 10-year yield hit 5% for the first time since 2007 while...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
SEDG : 33.01 (-3.79%)
AXP : 230.38 (+0.07%)
RF : 18.93 (+0.11%)
KNX : 48.35 (+2.07%)
MSFT : 449.78 (+0.92%)
GOOGL : 179.63 (+1.89%)
V : 275.22 (-0.58%)
KO : 62.77 (+0.95%)
META : 494.78 (-1.38%)
BA : 176.56 (+0.15%)
MarketBeat: Week in Review 12/12 - 12/16

A triple-witching day means it could be a rough end to a trading week. Before you step away for the holidays, here are some of the top articles from this week.

BILI : 18.14 (+6.39%)
PLAY : 40.99 (-3.33%)
MULN : 2.68 (unch)
NVDA : 126.57 (-3.22%)
AMD : 161.23 (-0.34%)
LULU : 311.82 (+0.34%)
TSCO : 281.56 (+0.47%)
HARP : 23.01 (+0.09%)
KSS : 22.87 (+2.69%)
Harpoon Therapeutics Remains Volatile After Promising News

Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.

HARP : 23.01 (+0.09%)
AMGN : 308.16 (-0.56%)
GILD : 70.67 (+3.18%)
REGN : 1,053.14 (+0.84%)
VRTX : 468.71 (-0.57%)
MRNA : 133.40 (-0.74%)
ABBV : 170.39 (-1.01%)
Three Small-Cap Biotech Stocks to Consider Now

This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023 

HARP : 23.01 (+0.09%)
HTGM : 0.4800 (-20.00%)
ABEO : 4.58 (+1.33%)
Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma

Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development

HARP : 23.01 (+0.09%)
Pre-Market Brief: Stocks Mixed As Investors Await Inflation Data, Fed meeting

December S&P 500 futures (ESZ22) are trending up +0.26% this morning after three major US benchmark indices closed lower on Friday, notching their biggest weekly drop in more than a month, as hotter-than-anticipated...

ESZ22 : 3,871.47s (-0.66%)
HARP : 23.01 (+0.09%)
HZNP : 116.30 (+0.04%)
AMGN : 308.16 (-0.56%)
GPC : 141.43 (+0.01%)
RH : 215.97 (-0.85%)
ULTA : 383.85 (+1.44%)
LI : 17.87 (-0.89%)
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting ...

HARP : 23.01 (+0.09%)

Business Summary

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body's immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform,...

See More

Key Turning Points

3rd Resistance Point 23.05
2nd Resistance Point 23.04
1st Resistance Point 23.02
Last Price 23.01
1st Support Level 22.99
2nd Support Level 22.98
3rd Support Level 22.96

See More

52-Week High 23.21
Last Price 23.01
Fibonacci 61.8% 15.53
Fibonacci 50% 13.16
Fibonacci 38.2% 10.79
52-Week Low 3.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar